Study guide
9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
Key Takeaways Explain This Topic AI
Methylergonovine is absolutely contraindicated in any hypertensive disorder, and carboprost is absolutely contraindicated in asthma; misoprostol is safe in both.
Tranexamic acid 1 g intravenously over 10 minutes must be given within 3 hours of birth, because the WOMAN trial showed the survival benefit is lost beyond that window.
Carboprost is 250 mcg intramuscularly every 15 to 90 minutes to a maximum of 8 doses, and misoprostol for hemorrhage is 800 to 1,000 mcg rectally or 600 mcg oral or sublingual.
A Bakri balloon is inflated with 300 to 500 mL of warm saline, never air, and a positive tamponade test is drainage falling below about 50 mL per hour.
Massive transfusion uses a 1:1:1 ratio of red cells, plasma, and platelets, targeting hemoglobin above 8 g/dL, platelets above 50,000, fibrinogen above 150 to 200 mg/dL, and core temperature above 36 degrees Celsius.
Last updated: September 2026
Stepwise Resuscitation Algorithm: The Midwifery Bundle
The American College of Obstetricians and Gynecologists (ACOG) and the California Maternal Quality Care Collaborative (CMQCC) establish a four-stage clinical algorithm for managing obstetric hemorrhage.
Stage 0: Universal Prevention & Risk Assessment
Active management of the third stage of labor (AMTSL) for all births: (1) prophylactic oxytocin administration (10 IU IM or 10–40 IU IV in 1,000 mL crystalloid) upon delivery of the anterior shoulder or immediately following infant delivery, (2) gentle controlled cord traction with counter-traction on the supra-pubic abdomen (Brandt-Andrews maneuver), and (3) vigorous post-delivery fundal massage.
Stage 1: Recognition & Early Intervention
Triggers: Cumulative blood loss >500 mL (vaginal) or >1,000 mL (cesarean) with continued bleeding, or any vital sign deviation (HR ≥110 bpm, BP ≤85/45 mmHg, Shock Index ≥0.9).
Immediate Midwifery Actions:
Call for Assistance: Mobilize bedside nursing, second midwife, and obstetrician.
Bimanual Uterine Compression: Perform immediate vigorous external fundal massage. If atony persists, insert a sterile gloved hand into the vagina, form a fist in the anterior vaginal fornix, and compress the anterior uterine wall against the external hand pressing firmly against the posterior fundus through the abdominal wall.
Bladder Decompression: Insert an indwelling Foley catheter to empty the bladder. A distended bladder mechanically elevates and shifts the uterus laterally, directly preventing effective myometrial contraction.
Venous Access: Ensure two large-bore peripheral intravenous lines ( 16- or 18-gauge ) are patent.
Fluid Resuscitation: Infuse warm isotonic crystalloids (Lactated Ringer's) rapidly; avoid excessive unbuffered saline to prevent hyperchloremic acidosis.
Stat Laboratory Orders: Complete blood count (CBC), baseline coagulation panel (PT/INR, aPTT, fibrinogen), and Type & Crossmatch for 2 to 4 units of packed red blood cells (PRBCs).
Initiate First-Line Uterotonics: Escalate immediately along the pharmacologic sequence.
Pharmacologic Uterotonic Sequence & Contraindications
When uterine atony fails to resolve with fundal massage and oxytocin, second- and third-line uterotonics must be administered without delay. The certified nurse-midwife must master the dosing, route, physiological mechanism, adverse effect profiles, and strict absolute contraindications for each agent.
Medication Standard Dosing & Route Mechanism & Onset Common Side Effects Strict Absolute Contraindications & Midwifery Precautions
Oxytocin (Pitocin) 10 to 40 IU in 1,000 mL crystalloid IV infusion titrated rapidly (or 10 IU IM ) Binds to myometrial G-protein coupled oxytocin receptors; onset <1 min IV, 3–5 min IM Water intoxication (antidiuretic effect) with prolonged high doses, flushing, transient hypotension Do NOT administer as an undiluted IV push bolus (causes profound systemic vasodilation, acute hypotension, tachycardia, and cardiac arrhythmias). First-line for all PPH.
Methylergonovine (Methergine) 0.2 mg IM every 2 to 4 hours (max 5 doses); may be injected intramyometrially Ergot alkaloid inducing sustained, tetanic uterine contractions; onset 2–5 min IM Nausea, vomiting, severe cramping, diaphoresis, peripheral vasoconstriction STRICTLY CONTRAINDICATED in Hypertensive Disorders (chronic hypertension, gestational hypertension, preeclampsia, eclampsia) and coronary artery disease. Can cause acute hypertensive crisis, intracranial hemorrhage, and stroke.
15-methyl Prostaglandin F2α (Carboprost / Hemabate) 250 mcg (0.25 mg) IM or intramyometrially; repeat q15–90 min (max 8 doses = 2 mg) Synthetic prostaglandin F2α analogue causing intense smooth muscle contraction; onset ~15–30 min Severe watery diarrhea, nausea, vomiting, shivering, transient pyrexia, flushing STRICTLY CONTRAINDICATED in Active Asthma or reactive bronchospastic pulmonary disease. Causes potent smooth muscle constriction of the tracheobronchial tree, precipitating life-threatening bronchospasm and pulmonary edema. Relative contraindication: hepatic or renal disease.
Misoprostol (Cytotec) 800 to 1,000 mcg Rectally (PR) OR 600 mcg Oral / Sublingual (single dose) Synthetic prostaglandin E1 (PGE1) analogue; promotes strong myometrial contractility; onset 20–30 min PR Severe shivering/rigors, transient hyperpyrexia (temperature spike up to 40.0°C / 104°F), diarrhea Safe in asthma and hypertension. Caution: pyrexia and shivering can be confused with intrapartum chorioamnionitis or septic shock.
Tranexamic Acid (TXA) 1 g IV in 100 mL NS infused over 10 minutes ; repeat 1 g IV after 30 min if bleeding continues Antifibrinolytic; competitively inhibits plasminogen activation to stabilize fibrin clots Nausea, vomiting, visual disturbances, dizziness Administer within 3 hours of birth (WOMAN trial demonstrated maximum survival benefit; mortality increases if delayed >3 hours). Contraindicated in active thromboembolic disease or severe renal impairment.
[!CRITICAL] AMCB Exam Core Rule: Always check the patient's blood pressure and respiratory history prior to administering second-line uterotonics!
If the patient is HYPERTENSIVE (preeclampsia, gestational HTN, chronic HTN): NEVER give Methergine — use Carboprost or Misoprostol.
If the patient has ASTHMA or reactive airway disease: NEVER give Carboprost (Hemabate) — use Methergine (if normotensive) or Misoprostol.
Tranexamic Acid (TXA) & The WOMAN Trial
The World Maternal Antifibrinolytic (WOMAN) trial, a landmark randomized placebo-controlled trial of over 20,000 individuals with postpartum hemorrhage, transformed clinical practice:
Administration of 1 g IV tranexamic acid infused over 10 minutes significantly reduced maternal mortality due to bleeding by almost one-third when given early.
The 3-Hour Time Window: The survival benefit was greatest when TXA was administered as early as possible after bleeding onset. When administration was delayed beyond 3 hours postpartum, the survival benefit was completely lost , and a trend toward increased adverse events was observed.
Repeat Dosing: A second 1 g IV dose is administered if bleeding continues after 30 minutes, or if bleeding restarts within 24 hours of the initial dose.
TXA is an antifibrinolytic, not a uterotonic; it prevents the breakdown of established fibrin clots and should be administered in conjunction with, not as a replacement for, standard uterotonic agents.
Stage 2 & 3 Mechanical, Surgical & Transfusion Interventions
When uterine atony or lower uterine segment bleeding persists despite aggressive uterotonic therapy and bimanual compression, mechanical and surgical escalation is required. Surgical & Interventional Escalation Ladder
- ├── 1. Intrauterine Balloon Tamponade (Bakri Balloon filled with 300 - 500 mL sterile saline)
- ├── 2. Vacuum-Induced Uterine Tamponade (Jada system)
- ├── 3. Uterine Compression Sutures (B-Lynch or Hayman sutures)
- ├── 4. Stepwise Uterine Artery Ligation (O'Leary stitches) & Hypogastric Artery Ligation
- ├── 5. Interventional Radiology: Uterine Artery Embolization (UAE - if hemodynamically stable)
- └── 6. Emergency Peripartum Hysterectomy (Definitive life-saving intervention)
- 1. Intrauterine Balloon Tamponade (Bakri Balloon)
Mechanism: A sterile silicone balloon catheter designed specifically for the uterine cavity. When inflated, it exerts uniform inward-to-outward hydrostatic pressure against the endometrial vasculature and myometrial walls, arresting capillary and venous bleeding.
Placement & Inflation: The balloon is inserted through the cervix into the uterine cavity under ultrasound or direct tactile guidance. It is inflated with 300 to 500 mL of sterile warm saline (never air or carbon dioxide).
The "Tamponade Test": Following inflation, the central drainage lumen is connected to a collection bag. If bleeding stops or decreases to minimal serosanguinous drainage (<50 mL/hr), the test is positive (successful) . If vigorous, bright red blood continues to pour through the drainage port or around the balloon into the vagina, the test is negative, and immediate surgical intervention is indicated.
Maintenance: The balloon is typically left in place for 12 to 24 hours , accompanied by a continuous maintenance oxytocin infusion (to prevent uterine relaxation around the balloon) and broad-spectrum antibiotic prophylaxis.
2. Massive Transfusion Protocol (MTP)
Activated when blood loss exceeds 1,500 mL, shock index is ≥1.0, or there is clinical evidence of uncompensated shock and rapid ongoing hemorrhage.
The 1:1:1 Ratio: Modern damage-control resuscitation avoids excessive crystalloid infusion (which worsens hypothermia, acidemia, and dilutional coagulopathy). Blood products are transfused in a balanced 1:1:1 ratio : 1 unit of Packed Red Blood Cells (PRBCs) : 1 unit of Fresh Frozen Plasma (FFP) : 1 unit of Platelets .
Target Parameters: Maintain maternal hemoglobin >8.0 g/dL , platelet count >50,000/mcL , serum fibrinogen >150 to 200 mg/dL , and PT/INR <1.5 .
Cryoprecipitate: If serum fibrinogen remains <150–200 mg/dL despite FFP, administer 10 units of cryoprecipitate (rich in fibrinogen, factor VIII, and vWF).
Hypothermia & Acidosis Prevention: Active maternal warming (forced-air blankets, fluid warmers) to keep core temperature >36.0°C (96.8°F) , as coagulation factor enzymes become profoundly inactive in hypothermic and acidemic environments.